Approval Further Expands Obagi Medical’s Injectable Portfolio and Strengthens Its Position as a Leading Dermatological Megabrand LONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today
LONDON, June 01, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world's
Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD), today
A multi-city pop-up introducing consumers to the future of skincare and longevity innovation NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ: WALD)
Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 delivers advanced mineral protection with skincare benefits for daily defense NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leader in advanced skincare innovation, the originator of medical-grade skincare and
LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“ Waldencast ” or the “ Company ”), a global multi-brand beauty and wellness platform, announced today that it was notified by the staff of the U.S. Securities and Exchange Commission (the “ SEC ”) that they have concluded
The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leader in advanced skincare innovation, the originator of
ProMD’s multi-location physician led network will participate in Obagi’s ALOHA Program as part of a structured evaluation of MagIQ and integrated skincare protocols to providers across multiple states NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in
FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand
LONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open.
